These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 18755353

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA, Rafaeloff-Phail R, Rafizadeh-Montrose C, Rhodes G, Robey R, Rojo I, Rungta D, Snyder D, Wilbur K, Zhang T, Zink R, Warshawsky A, Brozinick JT.
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [Abstract] [Full Text] [Related]

  • 6. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.
    Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
    [Abstract] [Full Text] [Related]

  • 7. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
    Rasouli N, Kern PA, Elbein SC, Sharma NK, Das SK.
    Pharmacogenet Genomics; 2012 Jul; 22(7):484-97. PubMed ID: 22437669
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
    Gilardi F, Giudici M, Mitro N, Maschi O, Guerrini U, Rando G, Maggi A, Cermenati G, Laghezza A, Loiodice F, Pochetti G, Lavecchia A, Caruso D, De Fabiani E, Bamberg K, Crestani M.
    J Biol Chem; 2014 Mar 07; 289(10):6908-6920. PubMed ID: 24451380
    [Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM, Schiffrin EL.
    Vascul Pharmacol; 2006 Jul 07; 45(1):19-28. PubMed ID: 16782410
    [Abstract] [Full Text] [Related]

  • 11. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.
    Liu J, Wang LN.
    Cochrane Database Syst Rev; 2017 Dec 02; 12(12):CD010693. PubMed ID: 29197071
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.
    Borsting E, Cheng VP, Glass CK, Vallon V, Cunard R.
    Am J Physiol Renal Physiol; 2012 Mar 01; 302(5):F540-51. PubMed ID: 22169011
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
    Tureyen K, Kapadia R, Bowen KK, Satriotomo I, Liang J, Feinstein DL, Vemuganti R.
    J Neurochem; 2007 Apr 01; 101(1):41-56. PubMed ID: 17394460
    [Abstract] [Full Text] [Related]

  • 18. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA.
    Diabetes Care; 2006 May 01; 29(5):1016-23. PubMed ID: 16644631
    [Abstract] [Full Text] [Related]

  • 19. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.
    Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T.
    Diabetes; 2005 Dec 01; 54(12):3358-70. PubMed ID: 16306350
    [Abstract] [Full Text] [Related]

  • 20. Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model.
    Nakano Y, Arima T, Tobita Y, Uchiyama M, Shimizu A, Takahashi H.
    Int J Mol Sci; 2020 Jul 19; 21(14):. PubMed ID: 32707656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.